Pharma Stability: Insights, Guidelines, and Expertise
The shelf life, or expiration date, indicates the period during which a drug product maintains its identity, strength, quality, and purity. It influences labeling, market authorization, and patient safety. Regulatory authorities scrutinize shelf-life justifications to ensure they are based on valid, scientifically sound, and compliant data.
Click to read the full article.
Data trending refers to the statistical and visual monitoring of stability data over time to detect any changes or deviations from expected behavior. It involves tracking critical quality attributes (CQAs) such as assay, degradation products, dissolution, and moisture content across defined time intervals during real-time or accelerated studies.
Click to read the full article.
Quality by Design (QbD) is a systematic, science-based approach to pharmaceutical development that emphasizes product and process understanding. It aims to ensure predefined quality through the identification of Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs).
Click to read the full article.
Stability data is essential for establishing the shelf life, storage conditions, and quality profile of a drug product. In expedited pathways, regulatory agencies may accept limited real-time data supplemented by accelerated or bridging studies — provided the data is scientifically justified and aligned with ICH and agency-specific expectations.
Click to read the full article.
Managing stability studies manually via spreadsheets or isolated databases can result in missed pulls, inconsistent documentation, and non-compliant audit trails. Software solutions eliminate these risks by automating workflows, ensuring centralized data access, and enabling analytics.
Click to read the full article.
Stability study requirements vary based on the product’s target market, which is classified by climatic zones as defined by WHO and ICH. Emerging markets predominantly fall under the most stringent categories: Zone IVa and Zone IVb.
Click to read the full article.
Combination products comprise two or more regulated components — drug, device, or biological — that are physically or chemically combined, co-packaged, or otherwise intended for use together. Stability testing must demonstrate that all components remain effective and safe throughout the shelf life.
Click to read the full article.
Moisture-sensitive APIs and formulations exhibit physical or chemical instability in the presence of elevated relative humidity (RH). Common mechanisms include hydrolysis, deliquescence, aggregation, and microbial growth.
Click to read the full article.
In early pharmaceutical R&D, speed is critical. With multiple formulations under evaluation, developers must quickly identify those most likely to succeed. Accelerated stability testing provides a fast, cost-effective way to assess the relative stability of various prototypes under controlled stress conditions, allowing prioritization of robust candidates.
Click to read the full article.
While excipients are considered “inactive” ingredients, they can interact physically or chemically with the active pharmaceutical ingredient (API) under stress conditions such as heat, humidity, and light. These interactions can accelerate degradation or alter bioavailability, posing serious risks to product quality and patient safety.
Click to read the full article.